Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Videos|October 20, 2020
Complementing Your Psychotherapy
Author(s)Shawn Singh, JD
VistaGen Therapeutics CEO Shawn Singh discusses what he and VistaGen are doing to create and improve treatments that complement your practice.
Advertisement
Shawn K. Singh, JD, is the CEO of VistaGen Therapeutics, Inc.
To see more of what VistaGen is doing to improve the medicinal treatments for anxiety and depression, see
Advertisement
Related to this article
Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
2
Brain Trust: Therapeutic Drug Monitoring and Adherence in Schizophrenia, With Jonathan M. Meyer, MD
3
What Clinicians Need to Know About Postpartum Psychosis
4
AI as a Task-Replacing Tool for Psychiatric Care: A Conversation With Christoph Correll, MD
5